Neutrophil to lymphocyte ratio predicts disease progression following intra-arterial therapy of hepatocellular carcinoma

Autor: Sunil K. Geevarghese, Mary Ellen I. Koran, Matthew D. Taussig, Fil Banovac, Samdeep K. Mouli, Jennifer C. Baker, Andrew J. Lipnik, Daniel B. Brown, Asma Ahmad
Rok vydání: 2016
Předmět:
Oncology
Male
medicine.medical_specialty
Carcinoma
Hepatocellular
Time Factors
Neutrophils
Lymphocyte
Antineoplastic Agents
Logistic regression
Serology
03 medical and health sciences
0302 clinical medicine
Predictive Value of Tests
Risk Factors
Internal medicine
medicine
Humans
Lymphocyte Count
Lymphocytes
Neutrophil to lymphocyte ratio
Chemoembolization
Therapeutic
Aged
Retrospective Studies
Chi-Square Distribution
Hepatology
business.industry
fungi
Disease progression
Liver Neoplasms
Gastroenterology
Middle Aged
medicine.disease
Magnetic Resonance Imaging
medicine.anatomical_structure
Logistic Models
Treatment Outcome
030220 oncology & carcinogenesis
Hepatocellular carcinoma
Multivariate Analysis
Disease Progression
Biomarker (medicine)
030211 gastroenterology & hepatology
Female
Radiopharmaceuticals
business
Tomography
X-Ray Computed
Progressive disease
Zdroj: HPB : the official journal of the International Hepato Pancreato Biliary Association. 19(5)
ISSN: 1477-2574
Popis: Prospectively predicting response to intra-arterial therapy for hepatocellular carcinoma (HCC) is challenging. Neutrophil/lymphocyte ratio (NLR) is a serum biomarker that is associated with survival for multiple malignancies. It was hypothesized that increased NLR would be associated with early disease progression after intra-arterial therapy of HCC.The outcomes of 86 treatment-naïve patients who had chemoembolization or radioembolization of HCC between July 2013-July 2014 were reviewed. Pre-treatment laboratory tests and imaging were used to measure NLR, Child-Pugh (CP) score, tumor number and tumor size. High/low NLR groups were defined as3 and3 respectively. Follow-up imaging at two months with assessed response using modified response criteria in solid tumors (mRECIST).NLR3 was seen in 25/86 patients (range 3.0-21.6). NLR3 patients had a significantly higher baseline CP score. Comorbidities were otherwise similar between groups as was tumor number/size. Disease control was significantly worse (p = 0.014) with NLR3. Logistic regression for tumor response revealed NLR3 as the best predictor of early progression (p0.0001).NLR may be a serologic biomarker of early progressive disease after intra-arterial therapy of HCC. Future research should focus on outcomes by treatment type or potentially combining arterial therapies with ablation and/or targeted biologic agents.
Databáze: OpenAIRE
Externí odkaz: